Literature DB >> 27378601

Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.

Dai Chihara1, Jason R Westin1, Roberto N Miranda2, Chan Y Cheah1, Yasuhiro Oki1, Francesco Turturro1, Jorge E Romaguera1, Sattva S Neelapu1, Lorreta J Nastoupil1, Luis E Fayad1, M Alma Rodriguez1, Nathan H Fowler1, Robert Z Orlowski1, Michael Wang1, Fredrick B Hagemeister1, L Jeffrey Medeiros2, Michelle A Fanale1.   

Abstract

Entities:  

Keywords:  zzm321990ABVDzzm321990; zzm321990EPOCHzzm321990; gray-zone lymphoma; treatment

Mesh：

Substances：

Year:  2016        PMID： 27378601      PMCID： PMC5920532          DOI： 10.1111/bjh.14226

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

Authors:  Andrew M Evens; Jennifer A Kanakry; Laurie H Sehn; Athena Kritharis; Tatyana Feldman; Aimee Kroll; Randy D Gascoyne; Jeremy S Abramson; Adam M Petrich; Francisco J Hernandez-Ilizaliturri; Zeina Al-Mansour; Camille Adeimy; Jessica Hemminger; Nancy L Bartlett; Anthony Mato; Paolo F Caimi; Ranjana H Advani; Andreas K Klein; Chadi Nabhan; Sonali M Smith; Jesus C Fabregas; Izidore S Lossos; Oliver W Press; Timothy S Fenske; Jonathan W Friedberg; Julie M Vose; Kristie A Blum
Journal:  Am J Hematol       Date:  2015-09       Impact factor: 10.047

2.  A prospective study of mediastinal gray-zone lymphoma.

Authors:  Wyndham H Wilson; Stefania Pittaluga; Alina Nicolae; Kevin Camphausen; Margaret Shovlin; Seth M Steinberg; Mark Roschewski; Louis M Staudt; Elaine S Jaffe; Kieron Dunleavy
Journal:  Blood       Date:  2014-07-14       Impact factor: 22.113

3.  Mediastinal gray zone lymphoma.

Authors:  Leticia Quintanilla-Martinez; Falko Fend
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

4.  High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Authors:  Jorge E Romaguera; Luis Fayad; Maria A Rodriguez; Kristine R Broglio; Frederick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth L Katz; Harish Gagneja; Barry I Samuels; Terry L Smith; Fernando F Cabanillas
Journal:  J Clin Oncol       Date:  2005-09-06       Impact factor: 44.544

5.  Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.

Authors:  Alexandra Traverse-Glehen; Stefania Pittaluga; Philippe Gaulard; Lynn Sorbara; Miguel A Alonso; Mark Raffeld; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2005-11       Impact factor: 6.394

6.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Authors:  Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245
  6 in total
  3 in total

1.  Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.

Authors:  Nobumasa Hojo; Makoto Nagasaki; Yasuha Mihara
Journal:  World J Clin Cases       Date:  2022-06-16       Impact factor: 1.534

Review 2.  "Do Not Ignore Musculoskeletal Pain"-Initial Presentation of a Rare Malignant Disease: Case Report and Literature Review.

Authors:  Ishan Patel; Arda Akoluk; Vandan Upadhyaya; Shraddhadevi Makadia; Steven Douedi; Taliya Farooq; Daniel Flynn; Michael Levitt; Mohammad A Hossain
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

3.  A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy.

Authors:  Rajiv M Mallipudi; Lance Alquran; Vishnu A Shenoy; Lori A Leslie; John A Conti
Journal:  Case Rep Oncol Med       Date:  2019-04-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.